IMUNON Prepares for R&D Day to Showcase Cancer Research
![IMUNON Prepares for R&D Day to Showcase Cancer Research](https://investorshangout.com/images/blog/ihnews-IMUNON%20Prepares%20for%20R&D%20Day%20to%20Showcase%20Cancer%20Research.jpg)
IMUNON to Host R&D Day in New York City
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, is poised to host its Research and Development (R&D) Day at the prestigious Harvard Club in New York City. This event will take place to explore the potential of IL-12, an innovative treatment approach for advanced ovarian cancer. The program is set to engage leading experts in the field along with key oncology figures who will present important insights from the ongoing OVATION 2 Study.
Insights on OVATION 2 Study
The R&D Day will present top-line data from the randomized Phase II OVATION 2 Study that have resonated within the clinical community. This research indicates a significant improvement in patient outcomes, showing an 11.1-month increase in median overall survival (OS) for the intent-to-treat population. These findings represent a 35% enhancement in survival rates among patients battling advanced stages of ovarian cancer.
Engaging with Experts
A highlight of the R&D Day will be discussions featuring ovarian cancer thought leaders and principal investigators from the Phase 2 OVATION 2 Study of IMNN-001. Together, they will analyze the results from the study and how this data will shape the plans for the forthcoming Phase 3 registration study. Attendees will also learn about the strategic role that IMNN-001 could play in enhancing treatment protocols for patients with advanced ovarian cancer.
Networking Opportunities
In addition to informative presentations, the event emphasizes the importance of in-person attendance as a crucial opportunity for networking and direct engagement with the organization’s management and speakers. For those unable to make it in person, virtual participation will be available, ensuring that all interested parties can gain access to vital information.
About IMUNON and Its Innovative Approach
IMUNON is dedicated to advancing a range of innovative treatments that leverage the body’s immune system to promote safe, effective, and durable responses against various human diseases. This approach distinctively sets it apart from traditional therapies. At the forefront of IMUNON's initiatives is the development of non-viral DNA technology.
TheraPlas® and PlaCCine® Modalities
Among its pioneering efforts, IMUNON is working on TheraPlas®, designed for coding cytokines and other therapeutic proteins targeting solid tumors where immunological methodologies show promise. Additionally, PlaCCine® is being developed for the delivery of DNA-coded viral antigens, intending to prompt robust immunological responses for improved patient outcomes.
Current Clinical Trials
The Company is advancing its lead clinical program, IMNN-001, which is a DNA-based immunotherapy designed specifically for the treatment of localized advanced ovarian cancer. This innovative treatment has successfully completed Phase 2 clinical studies. IMNN-001 functions by instructing the body to generate durable levels of potent cancer-fighting molecules within the tumor site, including interleukin-12 and interferon gamma. In addition to cancer treatments, IMUNON has initiated a first-in-human study for its COVID-19 booster vaccine, known as IMNN-101.
Future Directions and Contact Information
IMUNON is committed to evolving its technologies and enhancing the application of plasmid DNA, all aimed at better serving patients with challenging medical conditions. For additional information about their innovative therapies and ongoing studies, the company encourages interested parties to visit their official website.
Contact Details
For direct inquiries, stakeholders can reach out to:
David Gaiero
IMUNON, Inc.
Phone: 978-376-6352
Email: dgaiero@imunon.com
Kim Sutton Golodetz
LHA Investor Relations
Phone: 212-838-3777
Email: kgolodetz@lhai.com
Frequently Asked Questions
What is the purpose of IMUNON's R&D Day?
The R&D Day aims to present the latest data on ovarian cancer treatments, specifically highlighting the OVATION 2 Study and its implications for future research.
What are the key findings from the OVATION 2 Study?
The study reported an 11.1-month increase in median survival for patients, indicating a 35% improvement for those with advanced ovarian cancer.
Who will be presenting at the R&D Day?
Experts in the field of ovarian cancer, including thought leaders and principal investigators from important studies, will share their insights and research findings.
Will there be an option for virtual attendance at the event?
Yes, IMUNON has arranged for virtual participation for those unable to attend in person.
How does IMNN-001 work?
IMNN-001 is a DNA-based immunotherapy that instructs the body to produce cancer-fighting molecules directly at the tumor site to combat advanced ovarian cancer.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Par Pacific Holdings to Attend Key Investor Conferences
- Celularity Welcomes Richard J. Berman to Board of Directors
- Silvano Fashion Group Reports Q2 and 6M 2024 Financial Performance
- CrowdStrike Adjusts Revenue Forecast Amidst Market Challenges
- Market Updates: Technology Stocks Struggle Amid Earnings Reports
- HP Inc. Focuses on Cost Cuts and AI PCs for Growth
- Nvidia's Revenue Forecast: Key Insights and Market Reaction
- HII Welcomes Labor and Navy Secretaries for Workforce Development
- iTeos Therapeutics to Engage Investors in Upcoming Conferences
- Greystone Housing Impact Investors LP Shares Schedule K-3